Enoxaparin
Portal Vein Thrombosis
Institute of Liver and Biliary Sciences, Indiaother_biologicalPhase 4 / ApprovedActive
BB
64/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 52/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the Portal Vein Thrombosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Sorafenib First Affiliated Hospital of Zhejiang University | Phase 4 | BBB |
Lenvatinib First Hospital of China Medical University | Phase 4 | BBB |
WARFARIN Kafrelsheikh University | Phase 4 | BB |
NADROPARIN Shanghai Zhongshan Hospital | Phase 4 | BB |
Apixaban Asian Institute Of Medical Sciences | Phase 4 | B |
View all 26 →
Same molecule, other indications
Enoxaparin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →